Entacapone - Another Parkinson's medication associated with lymphocytic colitis

Alessandro F Fois; Rod Conrad; Toni Hampe

doi:10.1016/j.parkreldis.2021.09.010

Entacapone - Another Parkinson's medication associated with lymphocytic colitis

Parkinsonism Relat Disord. 2021 Oct:91:83-84. doi: 10.1016/j.parkreldis.2021.09.010. Epub 2021 Sep 15.

Authors

Alessandro F Fois¹, Rod Conrad², Toni Hampe³

Affiliations

¹ Movement Disorder Unit, Westmead Hospital, Cnr Hawkesbury and Darcy Road, Westmead, NSW, 2145, Australia; Sydney Medical School, The University of Sydney, NSW, 2006, Australia; St Stephen's Hospital, Hervey Bay, Urraween, QLD, 4655, Australia. Electronic address: alessandro.fois@sydney.edu.au.
² Sullivan Nicolaides Pathology, 24 Hurworth Street, Bowen Hills, QLD, 4006, Australia.
³ St Stephen's Hospital, Hervey Bay, Urraween, QLD, 4655, Australia.

PMID: 34543852
DOI: 10.1016/j.parkreldis.2021.09.010

Abstract

In response to the report of Ong and colleagues of a series of patients with levodopa/dopa decarboxylase inhibitor associated microscopic colitis, we report a case of entacapone associated microscopic colitis. We agree that chronic diarrhoea in patients with Parkinson's disease should prompt consideration of drug-induced microscopic colitis as the cause.

Keywords: COMT inhibitors; Entacapone; Lymphocytic colitis; Microscopic colitis; Parkinson's disease.

Publication types

Letter
Comment

MeSH terms

Antiparkinson Agents / adverse effects
Catechols / adverse effects
Colitis, Lymphocytic*
Enzyme Inhibitors
Humans
Levodopa / adverse effects
Nitriles
Parkinson Disease* / complications
Parkinson Disease* / drug therapy

Substances

Antiparkinson Agents
Catechols
Enzyme Inhibitors
Nitriles
Levodopa
entacapone